{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T02:05:17Z","timestamp":1766023517564,"version":"3.48.0"},"reference-count":29,"publisher":"e-Century Publishing Corporation","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Cancer Res"],"DOI":"10.62347\/ukfc7557","type":"journal-article","created":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T05:43:10Z","timestamp":1746510190000},"page":"1932-1938","source":"Crossref","is-referenced-by-count":0,"title":["Identification of novel NUP98::RARA fusion transcripts in acute promyelocytic leukemia with i(17)(q10) abnormality"],"prefix":"10.62347","volume":"15","author":[{"given":"Jifang","family":"Tu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"48694","published-online":{"date-parts":[[2025]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1182\/blood-2007-07-102798","article-title":"Acute promyelocytic leukemia: from highly fatal to highly curable","volume":"111","author":"Wang","year":"2008","unstructured":"Wang ZY and Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 2008; 111: 2505-2515.","journal-title":"Blood"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/nrc2943","article-title":"Acute promyelocytic leukaemia: novel insights into the mechanisms of cure","volume":"10","author":"Th&#xE9","year":"2010","unstructured":"de Thé H and Chen Z. Acute promyelocytic leukaemia: novel insights into the mechanisms of cure. Nat Rev Cancer 2010; 10: 775-783.","journal-title":"Nat Rev Cancer"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.5858\/arpa.2013-0345-RS","article-title":"Acute promyelocytic leukemia: a review and discussion of variant translocations","volume":"139","author":"Adams","year":"2015","unstructured":"Adams J and Nassiri M. Acute promyelocytic leukemia: a review and discussion of variant translocations. Arch Pathol Lab Med 2015; 139: 1308-1313.","journal-title":"Arch Pathol Lab Med"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"871590","DOI":"10.3389\/fonc.2022.871590","article-title":"Atypical rearrangements in APL-like acute myeloid leukemias: molecular characterization and prognosis","volume":"12","author":"Guarnera","year":"2022","unstructured":"Guarnera L, Ottone T, Fabiani E, Divona M, Savi A, Travaglini S, Falconi G, Panetta P, Rapanotti MC and Voso MT. Atypical rearrangements in APL-like acute myeloid leukemias: molecular characterization and prognosis. Front Oncol 2022; 12: 871590.","journal-title":"Front Oncol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3390\/genes14010046","article-title":"Acute promyelocytic leukemia with rare genetic aberrations: a report of three cases","volume":"14","author":"Liu","year":"2022","unstructured":"Liu G, Liu L, Bartolo DD, Li KY and Li X. Acute promyelocytic leukemia with rare genetic aberrations: a report of three cases. Genes (Basel) 2022; 14: 46.","journal-title":"Genes (Basel)"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Zhu HH, Yang MC, Wang F, Lou YJ, Jin J, Li K and Zhang SZ. Identification of a novel NUP98-RARA fusion transcript as the 14th variant of acute promyelocytic leukemia. Am J Hematol 2020; 95: E184-E186.","DOI":"10.1002\/ajh.25807"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"3341","DOI":"10.2169\/internalmedicine.55.7226","article-title":"Acute promyelocytic leukemia with i(17)(q10)","volume":"55","author":"Inamura","year":"2016","unstructured":"Inamura J, Ikuta K, Tsukada N, Hosoki T, Shindo M and Sato K. Acute promyelocytic leukemia with i(17)(q10). Intern Med 2016; 55: 3341-3345.","journal-title":"Intern Med"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.cancergencyto.2004.09.019","article-title":"Acute promyelocytic leukemia with PML-RARA fusion on i(17q) and therapy-related acute myeloid leukemia","volume":"159","author":"Lee","year":"2005","unstructured":"Lee GY, Christina S, Tien SL, Ghafar AB, Hwang W, Lim LC and Lim TH. Acute promyelocytic leukemia with PML-RARA fusion on i(17q) and therapy-related acute myeloid leukemia. Cancer Genet Cytogenet 2005; 159: 129-136.","journal-title":"Cancer Genet Cytogenet"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"5446","DOI":"10.12998\/wjcc.v10.i16.5446","article-title":"Pediatric acute myeloid leukemia patients with i(17)(q10) mimicking acute promyelocytic leukemia: two case reports","volume":"10","author":"Yan","year":"2022","unstructured":"Yan HX, Zhang WH, Wen JQ, Liu YH, Zhang BJ and Ji AD. Pediatric acute myeloid leukemia patients with i(17)(q10) mimicking acute promyelocytic leukemia: two case reports. World J Clin Cases 2022; 10: 5446-5455.","journal-title":"World J Clin Cases"},{"key":"ref9","unstructured":"Grimwade D, Biondi A, Mozziconacci MJ, Hagemeijer A, Berger R, Neat M, Howe K, Dastugue N, Jansen J, Radford-Weiss I, Lo Coco F, Lessard M, Hernandez JM, Delabesse E, Head D, Liso V, Sainty D, Flandrin G, Solomon E, Birg F and Lafage-Pochitaloff M. Characterization of acute promyelocytic leukemia cases lacking the classic t(15;17): results of the European Working Party. Groupe Français de Cytogénétique Hématologique, Groupe de Français d’Hematologie Cellulaire, UK Cancer Cytogenetics Group and BIOMED 1 European Community-Concerted Action “Molecular Cytogenetic Diagnosis in Haematological Malignancies”. Blood 2000; 96: 1297-1308."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"5328","DOI":"10.1073\/pnas.0400053101","article-title":"All-trans retinoic acid\/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia","volume":"101","author":"ZX","year":"2004","unstructured":"Shen ZX, Shi ZZ, Fang J, Gu BW, Li JM, Zhu YM, Shi JY, Zheng PZ, Yan H, Liu YF, Chen Y, Shen Y, Wu W, Tang W, Waxman S, De Thé H, Wang ZY, Chen SJ and Chen Z. All-trans retinoic acid\/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A 2004; 101: 5328-5335.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.hemonc.2020.05.007","article-title":"Genotypic and phenotypic characteristics of acute promyelocytic leukemia translocation variants","volume":"13","author":"Mannan","year":"2020","unstructured":"Mannan A, Muhsen IN, Barragán E, Sanz MA, Mohty M, Hashmi SK and Aljurf M. Genotypic and phenotypic characteristics of acute promyelocytic leukemia translocation variants. Hematol Oncol Stem Cell Ther 2020; 13: 189-201.","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1002\/cyto.b.22085","article-title":"Acute promyelocytic leukemia: Immunophenotype and differential diagnosis by flow cytometry","volume":"102","author":"Fang","year":"2022","unstructured":"Fang H, Wang SA, Hu S, Konoplev SN, Mo H, Liu W, Zuo Z, Xu J, Jorgensen JL, Yin CC, El Hussein S, Jelloul FZ, Tang Z, Medeiros LJ and Wang W. Acute promyelocytic leukemia: Immunophenotype and differential diagnosis by flow cytometry. Cytometry B Clin Cytom 2022; 102: 283-291.","journal-title":"Cytometry B Clin Cytom"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.semcancer.2014.02.009","article-title":"Nucleoporins and nucleocytoplasmic transport in hematologic malignancies","volume":"27","author":"Takeda","year":"2014","unstructured":"Takeda A and Yaseen NR. Nucleoporins and nucleocytoplasmic transport in hematologic malignancies. Semin Cancer Biol 2014; 27: 3-10.","journal-title":"Semin Cancer Biol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"6247","DOI":"10.1182\/blood-2011-07-328880","article-title":"NUP98 gene fusions and hematopoietic malignancies: common themes and new biologic insights","volume":"118","author":"SM","year":"2011","unstructured":"Gough SM, Slape CI and Aplan PD. NUP98 gene fusions and hematopoietic malignancies: common themes and new biologic insights. Blood 2011; 118: 6247-6257.","journal-title":"Blood"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"162","DOI":"10.4161\/nucl.19674","article-title":"Dynamics and diverse functions of nuclear pore complex proteins","volume":"3","author":"Chatel","year":"2012","unstructured":"Chatel G and Fahrenkrog B. Dynamics and diverse functions of nuclear pore complex proteins. Nucleus 2012; 3: 162-171.","journal-title":"Nucleus"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.tcb.2012.10.013","article-title":"The role of Nup98 in transcription regulation in healthy and diseased cells","volume":"23","author":"Franks","year":"2013","unstructured":"Franks TM and Hetzer MW. The role of Nup98 in transcription regulation in healthy and diseased cells. Trends Cell Biol 2013; 23: 112-117.","journal-title":"Trends Cell Biol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1086\/380648","article-title":"The breakpoint region of the most common isochromosome, i(17q), in human neoplasia is characterized by a complex genomic architecture with large, palindromic, low-copy repeats","volume":"74","author":"Barbouti","year":"2004","unstructured":"Barbouti A, Stankiewicz P, Nusbaum C, Cuomo C, Cook A, Höglund M, Johansson B, Hagemeijer A, Park SS, Mitelman F, Lupski JR and Fioretos T. The breakpoint region of the most common isochromosome, i(17q), in human neoplasia is characterized by a complex genomic architecture with large, palindromic, low-copy repeats. Am J Hum Genet 2004; 74: 1-10.","journal-title":"Am J Hum Genet"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"131","DOI":"10.18632\/oncotarget.28295","article-title":"Addendum: prognostic significance of isochromosome 17q in hematologic malignancies","volume":"14","author":"Koczkodaj","year":"2023","unstructured":"Koczkodaj D, Muzyka-Kasietczuk J, Chocholska S and Podhorecka M. Addendum: prognostic significance of isochromosome 17q in hematologic malignancies. Oncotarget 2023; 14: 131.","journal-title":"Oncotarget"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.cancergen.2015.08.001","article-title":"Acute promyelocytic leukemia with isochromosome 17q and cryptic PML-RARA successfully treated with all-trans retinoic acid and arsenic trioxide","volume":"208","author":"Shepshelovich","year":"2015","unstructured":"Shepshelovich D, Oniashvili N, Parnes D, Klein A, Muchtar E, Yeshaya J, Aviram A, Rabizadeh E and Raanani P. Acute promyelocytic leukemia with isochromosome 17q and cryptic PML-RARA successfully treated with all-trans retinoic acid and arsenic trioxide. Cancer Genet 2015; 208: 575-579.","journal-title":"Cancer Genet"},{"key":"ref20","unstructured":"Tang Y, Wang Y, Hu L, Meng F, Xu D, Wan K, Huang L, Li C and Zhou J. Acute promyelocytic leukemia with cryptic t(15;17) on isochromosome 17: a case report and review of literature. Int J Clin Exp Pathol 2015; 8: 15294-15300."},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1007\/s00277-011-1210-7","article-title":"Arsenic trioxide may improve the prognosis of APL with ider(17)(q10): report of a rare adult case of acute promyelocytic leukemia with ider(17)(q10)t(15;17) showing poor response to all-trans retinoic acid","volume":"90","author":"Tong","year":"2011","unstructured":"Tong H, Li K, Mei C, Wang H, Chen Z and Jin J. Arsenic trioxide may improve the prognosis of APL with ider(17)(q10): report of a rare adult case of acute promyelocytic leukemia with ider(17)(q10)t(15;17) showing poor response to all-trans retinoic acid. Ann Hematol 2011; 90: 1493-1494.","journal-title":"Ann Hematol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1007\/s12185-023-03696-7","article-title":"Risk factors and remaining challenges in the treatment of acute promyelocytic leukemia","volume":"120","author":"Yokoyama","year":"2024","unstructured":"Yokoyama Y. Risk factors and remaining challenges in the treatment of acute promyelocytic leukemia. Int J Hematol 2024; 120: 548-555.","journal-title":"Int J Hematol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"3433","DOI":"10.1182\/bloodadvances.2021006682","article-title":"Effect of additional cytogenetic abnormalities on survival in arsenic trioxide-treated acute promyelocytic leukemia","volume":"6","author":"Epstein-Peterson ZD","year":"2022","unstructured":"Epstein-Peterson ZD, Derkach A, Geyer S, Mrózek K, Kohlschmidt J, Park JH, Rajeeve S, Stein EM, Zhang Y, Iland H, Campbell LJ, Larson RA, Poiré X, Powell BL, Stock W, Stone RM and Tallman MS. Effect of additional cytogenetic abnormalities on survival in arsenic trioxide-treated acute promyelocytic leukemia. Blood Adv 2022; 6: 3433-3439.","journal-title":"Blood Adv"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/978-3-030-78311-2_3","article-title":"Acute promyelocytic leukemia: update on risk stratification and treatment practices","volume":"181","author":"Salhotra","year":"2021","unstructured":"Salhotra A and Mei M. Acute promyelocytic leukemia: update on risk stratification and treatment practices. Cancer Treat Res 2021; 181: 45-55.","journal-title":"Cancer Treat Res"},{"key":"ref25","unstructured":"Sanz MA, Lo Coco F, Martín G, Avvisati G, Rayón C, Barbui T, Díaz-Mediavilla J, Fioritoni G, González JD, Liso V, Esteve J, Ferrara F, Bolufer P, Bernasconi C, Gonzalez M, Rodeghiero F, Colomer D, Petti MC, Ribera JM and Mandelli F. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood 2000; 96: 1247-1253."},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1016\/j.jgo.2020.03.019","article-title":"Treatment of acute promyelocytic leukemia in older patients: recommendations of an International Society of Geriatric Oncology (SIOG) task force","volume":"11","author":"Klepin","year":"2020","unstructured":"Klepin HD, Neuendorff NR, Larson RA, Hamaker ME, Breccia M, Montesinos P and Cordoba R. Treatment of acute promyelocytic leukemia in older patients: recommendations of an International Society of Geriatric Oncology (SIOG) task force. J Geriatr Oncol 2020; 11: 1199-1209.","journal-title":"J Geriatr Oncol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1080\/14656566.2021.1961744","article-title":"Drug treatment options for acute promyelocytic leukemia","volume":"23","author":"Ferrara","year":"2022","unstructured":"Ferrara F, Molica M and Bernardi M. Drug treatment options for acute promyelocytic leukemia. Expert Opin Pharmacother 2022; 23: 117-127.","journal-title":"Expert Opin Pharmacother"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/s41408-021-00514-3","article-title":"Acute promyelocytic leukemia current treatment algorithms","volume":"11","author":"Yilmaz","year":"2021","unstructured":"Yilmaz M, Kantarjian H and Ravandi F. Acute promyelocytic leukemia current treatment algorithms. Blood Cancer J 2021; 11: 123.","journal-title":"Blood Cancer J"}],"container-title":["American Journal of Cancer Research"],"original-title":[],"link":[{"URL":"https:\/\/e-century.us\/files\/ajcr\/15\/4\/ajcr0163299.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T02:00:16Z","timestamp":1766023216000},"score":1,"resource":{"primary":{"URL":"https:\/\/e-century.us\/files\/ajcr\/15\/4\/ajcr0163299.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":29,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.62347\/ukfc7557","relation":{},"ISSN":["2156-6976"],"issn-type":[{"type":"electronic","value":"2156-6976"}],"subject":[],"published":{"date-parts":[[2025]]}}}